HBOT Conversations:
Dr. Hemal Mehta & Vibrant Health University
Dr. Hemal Mehta, MD is a Medical Director and an Independent Medical Examiner who focuses on pain management through a Regenerative medicine approach. Dr. Mehta is Board Certified in Physical Medicine and Pain Management. He received his Doctor of Medicine Degree from Ross University School of Medicine and completed his residency at East Carolina. He is the Medical Director of Vibrant Health of North Carolina, Tennessee Integrative Pain Institute, and TN Integrative Healthcare: Musculoskeletal and Regenerative Center; additionally, Dr. Mehta is the attending physician at Nashville Regenerative Orthopedics. Dr. Mehta is the 2013 recipient of the Inaugural Patient Appreciation Award at Nashville Academy of Medicine, and the 2004 Research Resident of the Year for East Carolina University. Dr. Mehta has extensive experience with stem cell proliferation, and angiogenesis. He has incorporated Ozone Injection Therapy, PRP (Platelet-Rich Plasma) Injections, Hyperbaric Oxygen Therapy and Regenerative Matrix and Regenerative Medicine Procedures – to name a few – into his integrative wellness & longevity medical practices.
Watch the Podcast
HBOT News Network welcomes back Dr. Hemal V. Mehta, M.D.; Medical Director of Vibrant Health of North Carolina. Dr. Mehta has joined HBOT News Network three times previously, where we focused heavily on the topics of fasting & regenerative medicine – see Dr. Mehta & Fasting, Dr. Mehta & Fasting (Part 2), and Dr. Mehta & Regenerative Medicine.
We are thrilled to have Dr. Mehta return to discuss Vibrant Health University. Vibrant Health University is a new start-up educational program through Vibrant Health. It is a way to help educate, not just the public, but also providers who are interested in performing regenerative therapies, regenerative injections, and providing an alternative to patients that’s not typically available.
Vibrant Health University wants to steer the medical field and general public away from the traditional heavy focus of pharmacology and surgical techniques; and educate people more on the integrative approaches available for regenerative therapies and regenerative treatments. What people can expect from Vibrant Health University (once it gets up and going), is a variety of online programs and podcasts they can watch. Then, if interested further, physicians can choose the option for an in-person educational program where Dr. Mehta or his team can visit the physician’s office (or the physician can visit them) and the physician can then witness live demonstrations, and learn how to do proper procedures for regenerative treatments, while incorporating their protocols into their treatment plans.
The courses at Vibrant Health University will be a structured program with a certification process. Dr. Mehta explains that they are planning to provide different tiers. For example, a lower tier, a medium tier, and a higher tier of education to providers based on their level of expertise, and based on how much knowledge they already have and how much they want to obtain. The ultimate goal of the program is to have the courses accredited by the appropriate certifying boards to count as continuing medical education for physicians.
Dr. Mehta & di Giralomo spend time discussing the importance of physician education, the continued benefits of fasting, and how to gain control of excessive inflammation.
Dr. Mehta remind us of Vibrant Health’s focus — to integrate traditional and non-traditional medicine to give each patient the best outlook and care. Ultimately, integrative medicine is integrating functional medicine and holistic therapies with what we’ve learned through history regarding how the human body works. God gave us everything we need to survive from the beginning of human life. Dr. Mehta ends this segment by explaining through the study of medicine, it’s incredibly difficult to not believe that there is a God or a higher power that has created this body. The human body is made to be able to tolerate all kinds of different injuries, in all kinds of different aspects of life, while adapting to the environment. There is absolutely no other machine that man has ever made that’s even similar to the divine healing capabilities of the human body.
If you’d like to know more about Vibrant Health University, please contact Vibrant Health at www.vibranthcs.com/contact/
Guest
Dr. Hemal Mehta
Subscribe Now, It’s Free!
Recent HBOT News
Clinical Trial – Estimation of the Effective Dose (ED) 95 of Intrathecal Hyperbaric Prilocaine 2% for Scheduled Cesarean Delivery.
Prilocaine is a local anesthetic drug which as an intermediate duration of action shorter
than bupivacaine 0,5% that is usually used for spinal anesthesia in scheduled cesarean
section. No study has yet investigated the use of hyperbaric (HB) prilocaine 2% for
intrathecal anesthesia in cesarean section. The aim of this study is to determine the
Effective Dose (ED) 95 of hyperbaric (HB) prilocaine 2% by using the Continual Reassessment
Method (CRM)
Clinical Trial – Dosing of Carcinogenic Complexes After Anesthesia With Intrathecal Hyperbaric Prilocaine.
The prilocaine is a very common local anesthetic that has the disadvantage of being
metabolized to o-toluidine, a human carcinogen.
Hyperbaric 2% prilocaine (HP), recently developped, is increasingly used for spinal
anesthesia in ambulatory surgery. But the formation of carcinogenic metabolites induced by
the hyperbaric prilocaine is not yet known. The aim of this study is to investigate whether
the intrathecal administration of 50 mg hyperbaric prilocaine induces also the formation of
carcinogenic complexes such as urinary o-toluidine and hemoglobin adducts from o-toluidine in
blood.
Comparison of Two Different Treatment Protocols Using Systemic and Intratympanic Steroids with and without Hyperbaric Oxygen Therapy in Patients with Severe to Profound Idiopathic Sudden Sensorineural Hearing Loss: A Randomized Controlled Trial.
Abstract: This study aimed to investigate the efficacy of simultaneous steroid and hyperbaric oxygen therapy (HBOT) in patients with severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL), which has a poor prognosis. Sixty patients diagnosed with...